Seminars in Hematology
Volume 44 , Pages S35-S45 , October 2007

Thrombopoietin Mimetic Agents in the Management of Immune Thrombocytopenic Purpura

  • Adrian Newland

      Affiliations

    • Corresponding Author InformationAddress correspondence to Adrian Newland, BA, MB, BCh, MA, FRCP (UK), FRCPath, Pathology and Pharmacy Building, 80, Newark St, The Royal London Hospital, London E1 2 ES, UK.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 STATEMENT OF CONFLICT OF INTEREST: Dr Newland has received grant/research support from Gilead and Amgen, and has received honoraria from Gilead and Amgen; he will discuss the unlabeled/unapproved use of rituximab, eltrombobag, and AMG 531 for idiopathic thrombocytopenic purpura.

PII: S0037-1963(07)00162-X

doi: 10.1053/j.seminhematol.2007.11.005

Seminars in Hematology
Volume 44 , Pages S35-S45 , October 2007

Article Tools

* Image Usage & Resolution